a daily pilgrimage carrying reagents and enzyme preparations. Indeed, César almost gave up early in his laboratory career when, in the course of making an enzyme preparation, he broke three expensive 5-litre flasks-there being only five such flasks available in the whole department. However, he went on to write up his dissertation, with several papers arising out of it, and gained a prize from the Argentine Chemical Society for the best thesis of the year.
SECOND PHD (CAMBRIDGE, 1958-60) : MORE ENZYMOLOGY After graduating, César was invited to head a new Department of Molecular Biology at the National Institute of Microbiology in Argentina. César accepted, but because he wanted to go abroad for postdoctoral research he took two years' leave of absence. On the recommendation of Stoppani, he applied to work with Malcolm Dixon FRS, who was head of the Enzyme Unit at the Sir William Dunn School of Biochemistry in Cambridge and with whom Stoppani had worked before the war. César was fortunate in obtaining a fellowship from the British Council, which paid for him to travel to England by boat in first-class accommodation (but would only pay the third-class fare for his spouse). César had some trouble understanding English at the beginning, but after reading and debating with Dixon (who, together with Edwin Webb, had just published a comprehensive volume, The enzymes), César agreed to study the kinetics and heavy metal activation of phosphoglucomutase. After suggesting this topic, Dixon-in his usual style-left César alone to work on the enzyme purification and kinetic studies. However, his first large-scale enzyme preparation was lost into the electric cold bath as a consequence of inattention occasioned by a champagne party to celebrate the first Nobel Prize for Fred Sanger FRS (for elucidating the amino acid sequence of insulin). Nevertheless, the first kinetic experiments with crystalline enzyme were successful and within a year César had data for three papers (2, 4, 5)*, of which he was sole author owing to Dixon's generosity. In this work, in contrast to previous reports, he discovered that it was only heavy metals that were displaceable by magnesium that could give rise to activation of the enzyme (rather than heavy metals per se).
The Cambridge Biochemistry Department provided an outstanding research environment in the late 1950s, harbouring luminaries such as Robin Hill FRS, Peter Mitchell (FRS 1974) and Joseph and Dorothy Needham (both FRS). Fred Sanger was then a central figure in the department and also possessed the only functional pH meter. Before long, César moved away from kinetic experiments (somewhat to Dixon's annoyance) and started collaborating with Sanger to define the active site of phosphoglucomutase. Sanger was undoubtedly to have a profound and long-lasting influence on César (figure 1). As the work proceeded, they jointly devised new techniques when needed, using large amounts of radioactivity (5 mCi of [ 32 P]phosphate) to label the enzyme. Thus, by adding the extract of 32 P-labelled potatoes to pure enzyme followed by extensive dialysis, radioactive enzyme-substrate complex could be obtained. The amino acid residues at the active site could then be defined with Sanger's methods. Although Koshland & Erwin (1957) had reported that the active site of phosphoglucomutase was similar to that of trypsin, Sanger doubted it. In fact, he and César found it to be Thr-Ala-Ser-His-Asp (as opposed to Asp-Ser-Gly) (1, 3). A good amount of data was obtained and César's dream of a Cambridge PhD came true in the unusually short time of only two years. PhD student of Sanger's) and Gerald Edelman had established the four-chain structure of immunoglobulin molecules but the molecular nature of their diversity was an enigma. In his Nobel lecture (29) , César stated that he was attracted to immunology because it seemed to revolve around a very simple experiment: take two different antibodies and compare their primary sequences. His sequence studies started; the enormous heterogeneity of immunoglobulin molecules kept him occupied for the rest of his life.
César's first paper on antibodies (7) was a study of the disulphide bridges in immunoglobulin light chains (Bence-Jones proteins). This was performed with the technical help of John Jarvis, who was to work with César as his research assistant throughout his career in Cambridge. This was the first of many papers in which protein chemical techniques were used to dissect the nature of antibodies, analysing their disulphide linkages, the differences between allotypes, the positions of the carbohydrate attachments, the mutations in heavy-chain disease proteins and the nature of antibody diversity as elucidated at the level of amino acid sequence. Some of this work was performed together with Richard Pink, his first English graduate student, and Blas Frangione, a postdoctoral scientist from the USA (11), and some also involved collaboration with his wife, Celia (for example (12, 13) ).
The work of Hilschmann & Craig (1965) and Putnam et al. (1966) and César's own work on immunoglobulin Ȕ chains (9, 10) revealed that sequence diversity in antibody polypeptide chains was largely confined to the amino-terminal portions. This clearly raised the issue of the mechanism by which such localized diversity was generated-an issue that was to receive wide attention among molecular biologists. Indeed, Sydney Brenner FRS in the Molecular Genetics Division at LMB was also ruminating about the problem and, in a unique example of their collaboration brokered by Francis Crick FRS, Brenner and Milstein wrote a letter to Nature (8) in which they resurrected and developed the somatic hypermutation theory due to Joshua Lederberg (ForMemRS 1979) of antibody diversification (Lederberg 1959) , suggesting a mechanism comprising targeted cutting of DNA and localized error-prone repair to account for the fact that antibody diversity was restricted to specific regions of a small number of genes (immunoglobulins). This was only one of the hypotheses put forward to account for the origin of antibody variation in the 1960s; other proposals included a contribution from gene rearrangement or gene conversion as well as a possibility of a major contribution from a multiplicity of antibody genes encoded in the germ line. Many of these ideas were discussed at the symposium on antibodies at Cold Spring Harbor in 1967.
Although the molecular nature of antibody diversity was initially investigated by polypeptide sequence analysis, attention was increasingly focused on immunoglobulin mRNA and on the encoding DNA. Elucidation of both the nature and the number of genes that encode antibodies in the inherited genome was crucial to furthering the understanding of the origin of antibody diversity. Together with Terry Rabbitts (FRS 1987) , who had arrived in the laboratory from the National Institute for Medical Research at Mill Hill, César used nucleic acid hybridization to estimate the number of germline genes encoding the antibody variable region. With the advent of molecular cloning and as a result of the work of Tonegawa (Hozumi & Tonegawa 1976) , Leder, Rabbitts and in several other laboratories, it became clear that functional antibody genes were assembled by programmed gene rearrangement during B lymphocyte development and that the multiplicity of germline gene segments together with imprecision at the site of V-D-J integration could account for much of antibody diversity. Whereas Terry Rabbitts continued to work on the organization and somatic rearrangement of immunoglobulin genes (with occasional collaboration with César), most of César's subsequent work on antibody gene diversification was devoted to IgV gene somatic hypermutation. Indeed, it was in considerable part due to César's own work that it became clear that antibody diversity was not solely achieved through the assembly of germline V-D-J gene segments but that a major contribution derived from localized hypermutation of the functionally rearranged immunoglobulin gene, underpinning the affinity maturation of antibodies that occurred after encounter with antigen.
THE SECRETORY SIGNAL PEPTIDE IN IMMUNOGLOBULINS
In 1972, after the completion, in collaboration with Jisnuson Svasti, of the elucidation of the complete polypeptide sequence of the Ȕ light chain of the MOPC21 myeloma protein (14), it became clear to César that it would be necessary to go beyond the sequencing of myeloma proteins for an understanding of the molecular basis of antibody diversity. He took the view that insight would come from structural studies of mRNA. The poly(A) tail on mRNA had not yet been discovered, and mRNA purification provided a substantial challenge. However, recent developments in translation systems in vitro helped the work (performed in collaboration with George Brownlee (FRS 1987) , Tim Harrison and Mike Mathews) considerably. Indeed, it was the difference in the size of the immunoglobulin light chain translation product obtained in vitro with their Krebs ascites extracts (which contained microsomes) as opposed to that obtained in their rabbit reticulocyte lysates (which did not; this system was set up with guidance from Tim Hunt FRS and Elma Cartwright) that provided the first evidence of a secretory signal sequence. In the resulting paper, published in Nature (15), Brownlee, Harrison, Mathews and Milstein proposed that the IgȔ light-chain polypeptide generated by in vitro translation was a precursor that would be converted to mature light chains by an enzymic activity in microsomes: in this paper they coined the term 'signal peptide'. They were unaware of the fact that, at a similar time and independently, Blobel & Sabatini (1971) hypothesized that, on the basis of the fact that proteins were secreted into the endoplasmic reticulum from membrane-bound polysomes, there must be information in the mRNA that determined translation on membrane-bound polysomes such as several codons located near the 5፱ end of membrane-bound but not free mRNA. After the work on the IgȔ light chain, César, in collaboration with Nick Cowan, went on to show that a similar situation regarding the effect of microsomes on the size of the in vitro translation product also applied to the immunoglobulin heavy chains (17). Subsequent work from many laboratories has shown that this proposal of an aminoterminal signal sequence holds true for the vast proportion of secreted polypeptides.
Although César's work using myeloma cells was also to lead him in other directions, he maintained a continuing interest in the mechanism of protein secretion. Thus, in collaboration with a series of postdoctoral visitors (Yair Argon, Oscar Burrone and Roberto Sitia), César used myeloma cells to study the mechanisms responsible for the quality control of immunoglobulin secretion.
SELECTION OF MYELOMA VARIANTS IN VITRO
By 1970, one could conclude that somatic events played a major role in the development of antibody diversity. It had also at last become accepted, after structural analysis, that myeloma proteins that composed a single species of immunoglobulin and were produced by plasma cell tumours were representative of antibody molecules. In contrast to myeloma cells, lymphoid tissue contained a great mixture of different B-cell clones secreting different immunoglobulin and antibody molecules into the blood. It was clearly technically advantageous to work with homogeneous myeloma proteins for structural studies of immunoglobulin. In the early 1970s César obtained a cultured cell line of the mouse myeloma cell line (MOPC21) that had been adapted to long-term tissue culture by Horibata & Harris (1970) , the tumour having originally been induced in BALB/c mice by Michael Potter at the National Institutes of Health (Potter & Boyce 1962 ). The MOPC21 cell line was grown up by César and George Brownlee to harvest mRNA (as well as acting as a source of IgG for the protein structural studies by others in the group).
César, with his new PhD student David Secher, initiated a project to study immunoglobulin diversification in cultured myeloma cells. The aim was to analyse the rate of somatic mutation in the MOPC21 immunoglobulin and to characterize the nature of any myeloma protein variants that might arise in vitro in the hope that these would reflect the antibody diversification process that occurred naturally in vivo. At this point Dick Cotton, a postdoctoral scientist from Australia interested in immunogenetics, arrived and joined the project. With the help of Abe Karpas, Cotton rapidly developed a talent for cell culture and succeeded in cloning MOPC21 cells in soft agar, a technique that allowed the isolation of MOPC21 mutants. Mutants were in fact obtained only rarely and even they did not resemble the major types of mutation that occurred naturally. Thus, after three months of continuous culture and analysis of immunoglobulin produced by 7000 clones, only five structural variants were isolated. However, none of these mutations was in the hypervariable region and most were deletions (16, 19 
MYELOMA FUSIONS AND MONOCLONAL ANTIBODIES
Research into fusion between different myeloma cell lines was originally initiated out of pure intellectual curiosity. But it was this curiosity-driven research that led to the technology for the derivation of monoclonal antibodies of predefined specificity, a technology with a huge impact on research, therapy, diagnostics and industry.
It had already been known for some years that although mammalian somatic cells are diploid for all autosomal genes, individual antibody-producing cells use only one of the two allelic copies of each immunoglobulin locus to produce functional antibody. This phenomenon was termed allelic exclusion, but the mechanism by which it was achieved was unknown. A second project undertaken by Dick Cotton was to study this question by fusing together two myeloma lines forming different immunoglobulin molecules, to investigate whether allelic exclusion would be maintained and whether there would be scrambling between the variable (V) and constant (C) regions of the two types of immunoglobulin molecule. To enable the selection of such fused cells, Cotton derived a variant of the mouse MOPC21 line that was sensitive to bromodeoxyuridine and obtained a rat myeloma cell line from Hervé Bazin (Belgium) to act as fusion partner (see Cotton 1994) . Fusions were performed with Sendai virus, which was provided by Abe Karpas. The resulting hybrid clones (hybridomas) showed co-dominant expression of both myeloma immunoglobulin products; allelic exclusion could not be detected, nor could scrambling of V-C regions (18). Thus, the linkage of V and C occurred early during B-cell differentiation, before immunoglobulin production commenced. In fact, the proteins formed by myeloma cells both in vitro and in vivo remain essentially constant. Cotton improved the methodology and guided Shirley Howe to select a different drugsensitive myeloma clone P3-X63Ag8, in this case resistant to 8-azaguanine. This enabled the derivation of mouse-mouse myeloma cell fusions, which yielded essentially the same results as the mouse-rat fusions.
César presented the results of this work on myeloma fusions in seminars, one of which was at the Basel Institute of Immunology. Inspired by the lecture, Georges Köhler enthusiastically asked to join César in Cambridge in 1974, after having finished his PhD in Basel. As always in César's laboratory, continuous discussions took place about research projects and, in a very close collaboration, Georges and César decided to try fusing normal spleen cells from mice that had been immunized with sheep red blood cells (SRBC) with the azaguanidine-sensitive myeloma clone MOPC21-P3-X63Ag8 (figure 2). The sensitivity of this myeloma clone to 8-azaguanine meant that hybrid cells could be selected in HAT (hypoxanthine, aminopterin, thymidine) medium. SRBC were chosen for immunization of BALB/c mice for good reasons because the strong antibody responses induced by SRBC had been extensively studied previously. Furthermore, the Jerne plaque-forming assay (Jerne & Nordin 1963 ) easily detects single antibody-forming cells in agar containing SRBC. Amazingly, the first fusion attempt was successful and three hybrid clones producing antibody against SRBC were detected. These hybrid clones also still produced the myeloma protein of the fusion partner. Georges then used 276
Biographical Memoirs Perhaps not immediately, but very soon, César realized the almost unlimited potential of this method for obtaining monospecific antibodies against almost any desired target antigen. The fusions were reproducible, having been repeated several times. Several colleagues interested in particular reagents or applications lined up to plan collaborations for the selection of particular monoclonal antibodies. But just before Georges was leaving, the fusions stopped working. Giovanni Galfrè, from Ruggero Ceppelini's laboratory in Turin, joined César's group early in 1976 with the intention of selecting monoclonal antibodies for use in human leukocyte antigen tissue typing. However, Galfrè had to start by getting the fusions working once more. Some of the culture media seemed to be toxic and, furthermore, the preparations of Sendai virus were running out. This stimulated Galfrè to introduce poly(ethylene glycol) as the fusion agent-an approach that had been recently described in the literature for other cell-cell fusions (Pontecorvo 1975) . Fortunately the fusions succeeded again and many monoclonal antibodies were obtained under Galfrè's supervision. Much effort was put into refining and developing the hybridoma process. A rat myeloma fusion partner was developed to allow the production of rat-rat hybridomas against mouse cell membranes, facilitating the derivation of monoclonal antibodies against mouse antigens. Secher's work in screening for antibody gene diversification of MOPC21 cells growing in culture had yielded a derivative clone that entirely lacked the secretion of functional immunoglobulin heavy chains. Together with Claudio Cuello, César pioneered the development of hybrid hybridomas, providing antibodies of dual specificity for use in immunocytochemistry (27).
CD1, THE FIRST HUMAN T-CELL MARKER
Numerous collaborations were initiated to obtain monoclonal antibodies against particular antigens of interest. The first collaborations were with Alan Williams (FRS 1990) in Oxford to make mouse antibodies against rat T cells (yielding a monoclonal antibody defining CD4 (22)) and with Jonathan Howard (FRS 1995) to select antibodies directed against the rat MHC (21). Then, in 1977, a collaboration with Andrew McMichael (FRS 1992) yielded the first differentiation marker on human lymphoid cells (T lymphocytes) to be defined (24) . The Journal of Experimental Medicine refused to publish this paper, but it became a citation classic after publication in the European Journal of Immmunology.
At the first Leukocyte Antigen Workshop, which was held in 1982, César enthusiastically joined the nomenclature section and insisted that this first monoclonal antibody identifying a human cell marker must be called CD1 (where CD defines a cluster of differentiation antigens). CD1 (which turned out to constitute a group of MHC class I-like proteins) remained a focus of César's research effort for the rest of his life. In this he was undeterred by the fact that for most of this period the function of CD1 remained wholly unknown. Immunochemical analysis indeed revealed that CD1 comprised both a heavy and a light chain. Although characterization of the light chain experienced a somewhat chequered history (with the lab ultimately demonstrating that it was identical to the ȋ 2 -microglobulin polypeptide of MHC class I), Franco Calabi, a postdoctoral colleague of César's from Genoa, used the anti-CD1 monoclonal antibody to isolate the complementary DNA for the CD1 heavy chain (31) . This achievement allowed a molecular characterization of the antigen and facilitated the discovery that CD1 was in fact a gene family, with five members in humans (32). Subsequently CD1 was shown to comprise a family of antigen-presenting restriction elements, with CD1 restricting recognition of lipids and glycolipids by natural killer (NK) T cells (reviewed in Porcelli & Modlin (1999) ). In collaboration with Alan (now Sir Alan) Fersht FRS and colleagues, who had devised improved methods for refolding denatured proteins, César prepared recombinant CD1. This led to the construction of tetramers of lipid-CD1 complexes, which enabled a study by Enzo Cerundolo and colleagues of lipid-specific NK T cell responses in health and disease (42) .
THE BIRTH OF ANTIBODY ENGINEERING
Although investigations into the molecular basis of antibody diversity were to form a theme running through nearly the entirety of César's scientific career, the near-fortuitous discovery of monoclonal antibodies had a major influence on the course of César's own research career, as well as obviously having an enormous impact on the rest of the scientific community. Not content with continuing to improve the monoclonal antibody technology and fostering its exploitation, César was quick to appreciate the enormous potential of combining recombinant DNA and monoclonal antibody technologies: one would no longer be restricted to simply immortalizing naturally occurring antibodies but the way was now open to designer antibodies-'antibodies à la carte' (25). Although César only made relatively modest efforts in this direction himself, he had a major influence in inspiring others in his ambience (Ermanno Gherardi, Michael Neuberger (FRS 1993) and Greg (now Sir Gregory) Winter (FRS 1990)) to pursue such goals (figure 3).
COMMERCIAL EXPLOITATION OF MONOCLONAL ANTIBODY TECHNOLOGY
There has been much discussion of the fact that publication of the Köhler and Milstein letter to Nature (20) was not preceded by a protective patent filing. There is no question but that, before the publication in Nature, César did alert the relevant authorities to the nature of his findings. Whatever the reason for the failure to patent, César was much hurt by any suggestion that the failure to patent monoclonal antibodies reflected any fault on his part. He was certainly not averse to filing patents and strongly felt the need to protect the interests of the MRC. He assisted in (and indeed initiated) the filing of several patents and was incensed at the sight of others obtaining patent protection for what he considered were at most trivial or obvious extensions of technologies that he had developed. Nevertheless, he did question whether the patenting of monoclonal antibody technology would have benefited mankind. He felt that for a fundamental enabling technology, patenting (and, in particular, a restrictive licensing policy) might well have inhibited rather than assisted its wide development and exploitation. Indeed, the absence of a patent probably encouraged the take-up of the technology but, even so, the therapeutic application of monoclonal antibodies (from which some of the greatest commercial rewards might have been expected) developed only after the initial patent would have expired.
However, it is beyond doubt that the technology has had enormous implications. Monoclonal antibodies have revolutionized clinical diagnostics with impacts on fields such as blood group typing, tumour classification, monitoring of cell subsets in the blood, and measurements of hormone levels (underpinning, for example, the home pregnancy-testing kits). The exploitation of monoclonal antibodies for therapy in humans has been somewhat slower to develop. However, after the elaboration of techniques for the production of recombinant humanized monoclonal antibodies (which, unlike antibodies of rodent origin, show little or no immunogenicity when administered to patients), this area of endeavour is now growing apace. Monoclonal antibodies are being widely used in the treatment of rheumatoid arthritis, breast cancer and B-cell lymphoma as well as other lymphomas and in the prevention of respiratory syncytial virus infection in premature infants, and a substantial proportion of small biotechnology companies are aiming for products in the antibody field. And, as was becoming evident in the final few years of César's life and much to his satisfaction, these developments are indeed bringing money back to the MRC and to the LMB in particular. The total royalty stream accruing to the MRC from licences granted to the various antibody engineering technologies (predominantly arising from methods developed in Greg Winter's laboratory) amounted to about £13 million in 2003, constituting the major proportion of the MRC's total royalty income from its intellectual property portfolio. 
THE MATURATION OF ANTIBODY AFFINITY
In the late 1970s, together with Pamela Hamlyn, César adapted Sanger's recently developed dideoxy-DNA sequencing technique to allow the elucidation of immunoglobulin V gene sequences in hybridomas by oligonucleotide-directed specific reverse transcription of total cellular messenger RNA (23) . He applied this technique of IgV gene sequence determination to hybridomas established at various times during the course of a mouse anti-hapten immune response. The hapten that he used was 2-phenyloxazolone, an experimental system that was brought to the laboratory by Matti Kaartinen, who came as a postdoctoral fellow from Olli Mäkelä's group in Helsinki. César, together with Claudia Berek and Gillian Griffiths, charted the accumulation of somatic mutations that occurred during the course of the anti-oxazolone response (26, 28, 30) . The databases of mutations accumulated allowed powerful conclusions to be drawn about the contribution of somatic mutation to antibody diversity without even, for many years, knowing the full extent of contributing germline V-gene diversity. Indeed, this work represented one of the major lines of evidence demonstrating the importance of somatic hypermutation for antibody affinity maturation. The mechanism by which the mutations led to affinity maturation was then investigated at the level of binding kinetics in collaboration with Jefferson Foote (work that also gave insights into the conformational diversity of individual antibodies) as well as at the structural level through a collaboration with César's fellowArgentinian and friend Roberto Poljak (33, 35, 40) . The studies constitute an elegant paradigm for the somatic evolution of protein specificity.
THE MECHANISM OF SOMATIC HYPERMUTATION
Although the analysis of antibody sequences in hybridomas revealed the importance of somatic mutation for affinity maturation, the molecular mechanism by which the diversification process occurred and, more specifically, how it was specifically targeted to the IgV genes remained a thorny problem. In the 1980s there were still no convincing experimental systems in vitro in which antibody somatic hypermutation could be recapitulated. It was the development of the technology for making transgenic mice that reopened a way of tackling the problem of defining the cis-acting regulatory sequences that recruited the hypermutation mechanism to the IgV gene. Michael Neuberger in LMB had already established a collaboration with Azim Surani (FRS 1990) at the Babraham Institute to use transgenic mice to analyse the cis-acting sequences regulating immunoglobulin gene expression. This strategy was extended to include an analysis of somatic mutation and formed the basis for a collaboration between César's and Neuberger's groups over a decade. The initial experiments were pioneered by Melanie Sharpe (34), a postdoctoral fellow who came across from Oxford at the suggestion of Alan Williams, and were continued by a graduate student in each of the two laboratories, Cristina Rada and Alex Betz. After her graduation in 1993, Cristina was to continue to work with César as a postdoctoral scientist until his death. The experiments revealed that some of the DNA sequences implicated in recruiting the mutator to the IgV gene were similar to those responsible for recruiting RNA polymerase (39) . The use of transgenes encoding nonfunctional immunoglobulin chains also gave insight into the actual spectrum of nucleotide substitutions introduced by the antibody mutator (removing the very heavy skewing effects of antigen selection) (36, 37) . The accumulation of large databases of such mutations became a hallmark of the strategy used, an approach made possible by the advent of the polymerase chain reaction (PCR) as well as by developments in DNA-sequencing technology. In addition, with Africa Gonzalez (a postdoctoral fellow from Spain), César initiated a shift away from mutation analysis with antigen-selected hybridomas and towards the analysis of mutation in populations of germinal-centre B cells in Peyer's patches, where immune responses to antigens in the gut are occur continuously without need of specific immunization (38). These various advances provided valuable information on the intrinsic sequence preferences of the antibody mutator, information that was chewed over ad nauseam in the hope that it would give insight into the mutation mechanism. This optimism was eventually rewarded. Comparison of the nucleotide substitution patterns in normal mice with those in mice deficient in the mismatch recognition protein MSH2 led to the proposal that somatic mutation occurred in two phases, the first predominantly targeted to C:G pairs, the second to A:T (41) . This dissection of the process into two phases proved critical to a shift away from a simple model of somatic mutation based on polymerase error (as in César's paper with Sydney Brenner (8)) and towards the unveiling of the DNA deamination mechanism.
About 18 months before César's death, Tasuku Honjo (together with collaborators in France and Japan) published a pair of papers revealing a newly identified B-cell-specific protein, AID, to be essential for the performance of both somatic mutation and immunoglobulin class switch recombination (Muramatsu et al. 2000; Revy et al. 2000) . Its mechanism of action was entirely unknown. One possibility was that it acted intimately in the antibody diversification process, working in the nucleus. This was evidently the possibility that César favoured. In his last paper, submitted to the Proceedings of the National Academy of Sciences only five days before his death, César (together with Cristina Rada and his long-term research officer John Jarvis) described experiments in which they introduced a gene encoding a fluorescently tagged AID into a hypermutating B cell line to see where the AID protein was located (43). It was exclusively detected in the cytoplasm. Despite this evidence to the contrary, César nevertheless proposed that the functional AID was acting in the nucleus, using sophistry to achieve an interpretation that accorded with his instincts. His instincts were, as so often, entirely correct (Neuberger 2003; Neuberger et al. 2003 ). César's nearly four decades of research in Cambridge therefore spanned the study of antibody diversification from its identification at the protein level through to the demonstration of the importance of somatic mutation to affinity maturation, a characterization of the intrinsic features of mutational process and the beginnings of the elucidation of the molecular mechanism.
THE PERSON AND THE LEGACY
César's official retirement date was 1995, when he stepped down from the Headship of the Protein and Nucleic Acid Chemistry Division and Deputy Directorship of the LMB. However, César continued to be highly active in the laboratory (figure 4) with the help of John Jarvis, his loyal technician since the mid-1960s, and Cristina Rada, his penultimate PhD student. During his later years, César usually returned home (which was just around the corner from the laboratory) to join his wife, Celia, for a quick lunch. Indeed, Celia had always played a very important role in César's career, joining him at many meetings, organizing his life outside the laboratory, providing constant support and close companionship and sharing his buoyant and youthful enthusiasm for life and science.
Only during his very last years did César give up working on Saturday mornings, often using the time instead to go to the Cambridge market to choose the fish for the weekend from his friend the fishmonger. César was indeed an enthusiastic cook and many will remember his outstanding paellas and the warm hospitality that he and Celia so frequently dispensed.
César greatly enjoyed the company of his friends and colleagues, and he retained his enthusiasm for science throughout his life: research remained his focus. Discussions with César were rarely short (although his style became more concise and incisive in later life) but they always had a characteristic quality. His iterative style of discussion (analogous to chewing over a bone that was looked at from every angle in the hope of finding a new morsel of flesh), his persistent questioning of received wisdom, his reluctance to follow the voguish view, his continual quest for interesting aspects of a problem that others might have overlooked or underestimated-all are qualities that have exerted great influence on the many scientists who passed through his laboratory or whom he encountered at scientific meetings. It was rare if one did not come away from the discussion without César having provided some novel and-usually-highly significant insights. This was true not only of scientific discussions but also when he joined walking tours in the Alps organized by Fritz Melchers (from the Basel Institute for Immunology). Just when the route to be taken had been decided upon and everyone had started up the mountain, César would look at his map and say 'just a moment, let us see', and an argument would then ensue. Although his style of oral discussion was marked by a frequent search for words with a lack of facility for bringing a conversation to a speedy conclusion (there was always an additional aspect of the problem to consider), he achieved great clarity, brevity and elegance in his written scientific work.
Friendship, conversation and scientific arguments were major themes in César's approach to science, with the style of discussion often assuming a more latin flavour as the discussions became more heated. Despite the length of his residence in the UK, César retained a strong Argentinian accent, although he was reluctant to speak Spanish in the laboratory itself. Although several attempts were made by senior figures in Argentina to persuade César to return to his native country, he was adamant that he wished to remain in the UK. Nevertheless, César put considerable time and effort into assisting science in Argentina, Spain and thirdworld countries, in particular by contributing to the Third World Academy of Sciences and to the Juan March Foundation.
During the latter decades of his life, César suffered serious cardiovascular disease. He did not let this compromise his enjoyment of life or his partaking in many of his favourite activities. He loved both opera and theatre, often attending performances in London and at the Cambridge Arts Theatre. On weekends he took pleasure in taking trips along East Anglian rivers and canals in his motor boat and in sailing trips with Fred Sanger. When having a defibrillator installed at Papworth Hospital, a consultant asked César what his profession had been. César answered without hesitation: 'I dabble a bit in science'. One of his long-term ambitions had been to try white-water rafting in Chile. However, on this expedition in 1992, he endured a heavy heart attack. Even after that experience César continued travelling, and a few months before his death he attended a prize-giving committee meeting at the Mahidol Foundation in Thailand, although feeling quite unwell. As himself a recipient of a multitude of major prizes, César greatly enjoyed contributing to the deliberations of many prize-awarding bodies.
As discussed above, César made a litany of scientific discoveries as well as pioneering and developing the technology for making monoclonal antibodies. He regarded Fred Sanger as the greatest scientific influence on his own career. César himself leaves a large school of scientists who were in turn strongly influenced by him. Through influence and by example, but not through any evident grand design, he shaped the Protein and Nucleic Acid Division of LMB. He was a member of this Division (originally the Protein Chemistry Division) for just short of four decades, serving it as postdoctoral fellow, group leader, Head of Sub-division and, finally, joint Head of Division (first with Fred Sanger and then with Terry Rabbitts) before reaching nominal retirement age. Although a very successful Head of Division and a major contributor to the workings of the LMB executive committee, César normally eschewed committees and had little affection for matters administrative. When a new committee or meeting about organizational issues was proposed, he frequently stated 'I oppose', before even learning the intended purpose of the proposed meeting.
The developments resulting from the application of monoclonal antibody technology gave great pleasure to César. The success of monoclonal antibodies in human therapy (which became a burgeoning industry in the latter years of César's life) was obviously a major satisfaction and was a development that César had encouraged others to pursue at many opportunities. César especially championed the exploitation and development of the hybridoma technology for diagnostic purposes, looking for new opportunities in ligand detection and purification. He was involved in the founding of Celltech but his most sustained contribution
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